Get started
ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1

ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

LLY trade ideas

Red Pill or Blue Pill?Red Pill first - let’s stick to some harsh realities, but using technical analysis only. Why the harsh crash? We were rejected at the Value Area high at $972, followed by another rejection at the 0.786 Fibonacci level at $916, along with the top of the flag pattern of this giant bull flag. This was an epic short for those that took it, strong technical confluence. We then began consolidating before another rejection of the POC - $776, we also lost the 21 week moving average. The rejection was on a large volume candle - so the bears are firmly in control, for now. This is a pivotal point since Lily had claimed the 21 week moving average in December 2020, and it was only just lost. Not good. Blue Pill - is there hope? I think so. In my opinion this is a giant bull flag pattern and eventually Eli Lilly will break all time highs, but that will take time to play out. Don't be mistaken, the bears are in full control. But we are now sitting on the first line of support - the 0.5 Fibonacci level at $641 and the VAL - so far we are holding. Is this the optimal entry for new longs? It's not a bad place to start building a position, if you want to be extremely aggressive. We have just dipped into my DEMAND ZONE box. Waiting for lower? Well that is likely given the downtrend volume. We could get an optimal entry between $557 to $599. We have a strong confluence of the 200 week moving average and the golden ratio pocket. I don't think we will lose the critical weekly support level, but if that is lost there isn't a lot of support below. I do firmly believe institutions will be stepping in here and buying aggressively. Of course a recession will change everything, but we are not there yet. So there's reasons to be optimistic for long term holders buying on dips, but don't expect a swift recovery. Not financial advice, always do what's best for you. Keep a close eye on this chart
NYSE:LLYLong
by NoFOMO_
12
LLY Ready to Break Out? Here's What the Chart Tells Us🚨 LLY Ready to Break Out? Here's What the Chart Tells Us Back in November 2024, we shared an idea warning that Eli Lilly (LLY) was facing some serious headwinds. Since then, the market has confirmed it, NYSE:LLY has spent nearly a year moving sideways , showing little strength to push the stock higher. But that period of consolidation may be coming to an end. Right now, NYSE:LLY is forming a classic flag (or channel) pattern in the middle of a longer-term bullish trend. Technically speaking, a breakout to the upside would project the price directly into the analyst consensus target, which currently ranges between $950 and $1,000 . That would be a strong continuation of the long-term uptrend! However, even without a breakout, this chart offers attractive trading opportunities inside the pattern. Buying near the bottom of the channel and selling near the top could yield gains of up to 25% , all while keeping risk low . Why? Because we can clearly define a support zone (shown in red) based on previous highs and high VRVP volume, which gives us a logical stop-loss area. 📈 Let’s not forget: LLY has already corrected around 30% from its all-time highs , and if price drops to the lower buy zone, that discount could increase to 35%, a level many long-term investors would find very attractive. Analyst sentiment remains strong, with a "Strong Buy" consensus rating and price targets nearing $1,000, making this setup one worth watching closely. 💬 Does this setup align with your view on NYSE:LLY ? 🚀 Hit the rocket if this helped you spot the opportunity and follow for more Chart Patterns and educational trade ideas!
NYSE:LLYLong
by TopChartPatterns
9
LLY Is Overbought ---$615 Put Play**💊 LLY WEEKLY TRADE IDEA — BEARISH PRESSURE BUILDING** 📉 **Sentiment:** Strong bearish lean (70% confidence) — low RSI, high volume distribution. 📊 **Institutional Flow:** 1.7x weekly volume, puts stacking near key strikes. ⚠ **Risk:** Gamma risk + oversold → expect high volatility. **🛠 Setup:** * **Direction:** PUT (Short bias) * **Strike:** \$615 * **Expiry:** 2025-08-15 * **Entry:** \$2.20 – \$2.40 * **PT:** \$3.30 (50-100% gain target) * **SL:** \$1.20 (\~40-50% loss cap) 📌 **Why?** * Daily RSI \~20, Weekly RSI \~33 → both falling * Institutional selling pattern confirmed * Bearish volume + neutral C/P ratio tilt 💡 *Timing is key — oversold = possible dead-cat bounce before breakdown to \$605 support.*
NYSE:LLYShort
by quantsignals
2
Rare Discount Below $700LLY’s sell-off today is driven by underwhelming data from its new oral GLP‑1 drug—but it came on the heels of an otherwise stellar earnings report and outlook upgrade. If you believe in Lilly’s leadership in obesity and diabetes treatments, its strong cash flows, and long-term drug development pipeline, this could be a compelling opportunity to buy at a discount. Rare discount at 15% below the monthly average with a price last seen in Feb 2024. Buy the dip back to $700s.
NYSE:LLYLong
by Audacity618
Conservative Bullish Case for Eli Lilly: A Pharmaceutical LeaderEli Lilly (LLY) is currently trading at $812.95, having recently shown strength by climbing from the mid-$700s to over $800 in the past month. The stock has established a key support zone in the $760-780 range while testing resistance around the current price level. Fundamental Strength LLY's recent performance is backed by solid fundamentals: Improving Profitability Metrics: The PE ratio has decreased from 135.9 in Q1 2024 to 70.2 in Q1 2025, indicating improved earnings efficiency despite the high valuation. Strong Gross Profit Margins: Consistently maintaining margins above 80% (82.5% in Q1 2025), demonstrating pricing power and operational efficiency. Impressive Earnings Growth: Q4 2024 showed a 113.7% year-over-year EPS growth, with Q1 2025 continuing the trend at 29.5% growth. Return on Equity: Q1 2025 ROE of 17.4% shows efficient use of shareholder capital. Catalysts for Continued Growth Recent developments support a bullish outlook: European Regulatory Progress: On July 25th, LLY received positive CHMP recommendation for donanemab in Alzheimer's treatment, opening a significant new market. Product Innovation Pipeline: The FDA approved a new dosing schedule for Kisunla (donanemab) on July 9th, enhancing its safety profile while maintaining efficacy. Pricing Strategy Optimization: LLY introduced flat-rate pricing for Zepbound at $499/month in June, potentially expanding market access. Strategic Acquisitions: The company's $1.3 billion acquisition of Verve Therapeutics expands its portfolio into gene editing for cardiovascular disease. Strong Analyst Support: 12 of 13 recent analyst ratings are "buy," with an average price target around $1,000, suggesting approximately 23% upside potential. Technical Setup The weekly chart shows LLY in a Stage 2 growth phase according to Weinstein analysis, with price consolidating after a strong uptrend. The recent price action has formed a potential base in the $760-780 range, with the stock now testing resistance. Conservative Trade Approach For investors seeking a measured entry into LLY: Entry Strategy: Consider a partial position at current levels ($810-815) with plans to add on any pullbacks to the $780 support zone. Position Sizing: Limit initial position to 50% of intended allocation to manage risk. Stop Loss: Place a protective stop below the recent support at $760 (approximately 6.5% below current price). Target: First target at $900 (10.7% upside), with potential for further gains to analyst consensus targets around $1,000 (23% upside). Risk Management: The 3:1 reward-to-risk ratio makes this a favorable setup for conservative investors. Risks to Consider While the outlook is positive, prudent investors should be aware of: Valuation Concerns: Despite PE ratio improvement, LLY still trades at a premium to the broader market. Competition: Novo Nordisk and emerging competitors are advancing their own weight management and diabetes treatments. Regulatory Scrutiny: Increased attention on GLP-1 drugs could impact growth trajectory. Political Risk: Potential pharmaceutical tariffs under a new administration could affect margins.
NYSE:LLYLong
by ImmaculateTony
1
LLY - Earnings upcoming, recent news makes this appealing📈 LLY — Eli Lilly & Co. Ticker: LLY | Sector: Biotech / Pharmaceuticals Date: July 26, 2025 Current Price: ~$813 Resistance Zone: $825 Support Zone: $740–$750 🧪 Recent Drug News 1. EMA Backs Alzheimer’s Drug Donanemab (Kisunla) The European Medicines Agency’s advisory committee has issued a positive opinion on donanemab for early Alzheimer's patients with confirmed amyloid pathology and fewer ApoE4 gene copies. This reverses a previous rejection and paves the way for a likely EU approval in the coming months. Data from TRAILBLAZER‑ALZ trials showed slower cognitive decline and improved safety with a modified dosing regimen, while Europe’s Alzheimer’s patient population is projected to nearly double by 2050. 2. Orforglipron Shows Promising Phase 3 Results Lilly’s investigational oral GLP‑1 therapy, orforglipron, achieved clinically significant results in Phase 3: A1C reductions of 1.3%–1.6% across doses, weight loss averaging 7.9% at the highest dose, and efficacy seen as early as four weeks. The safety profile was consistent with injectable GLP‑1 drugs, offering a powerful oral option for type 2 diabetes management. ⚡ Analyst & Market Recap (Past Week) HSBC issued a double downgrade, lowering its rating to "Reduce" and cutting its price target from $1,150 to $700, citing valuation concerns and competitive pressure in the weight-loss space. Erste Group downgraded LLY from “Buy” to “Hold,” slowing expectations around drug pipeline momentum. Despite this, other analysts maintain a positive outlook, with the average 12-month price target in the $1,012–$1,016 range, spanning a wide band from $700 to $1,190. Investor sentiment is shifting cautiously due to rising competition and high multiples. 🔍 Technical & Market Structure Based on the latest 30-minute chart: Price remains stuck within a sideways trading range, bounded by a resistance level near $825 and support in the $740–$750 area. Momentum is building but hasn’t broken through significant technical thresholds yet. ✅ Bullish Scenario Trigger: Break and hold above $825 Targets: $850 → $900 → $950 Catalysts: Oral GLP‑1 approval prospects, Alzheimers regulatory momentum, and possible drug trial successes ❌ Bearish Scenario Trigger: Breakdown below $740 Targets: $700 → $670 Risks Include: Rising competition from Novo Nordisk, slowing pipeline news, valuation compression, and analyst downgrades 🧠 Strategic Summary LLY is operating in a tight technical corridor, with the potential for volatility driven by both clinical and regulatory catalysts. The recent drug developments—donanemab's EMA advancement and orforglipron's strong Phase 3 results—may supply fuel for a bullish breakout if momentum shifts convincingly above $825. Conversely, bearish pressure may intensify if the downside at $740 breaks. Key levels to watch: breakout above $825 or failure below $740.
NYSE:LLYLong
by QuantAi-Trend
Eli Lilly (LLY) – Full Technical + Fundamental Analysis (July 20 I wanted to take a deeper dive into LLY and analyze more than just trendlines—looking into both the technical structure and the broader fundamentals of the stock. Sources: i have a list of sources at the end of my report Technical Breakdown: Current Price: ~$771.75 Resistance Zone: $950–970 prior rejection levels Support Zone: Strong: $760–765 (multiple historical rejections and rebounds). Secondary: $717 (previous bounce area). Trendline: Steadily rising higher-lows, supporting price above $760. RSI: Recently cooled from 79 (overbought) to ~51 (neutral), suggesting balanced conditions. No immediate overbought or oversold signals. Chart Pattern Summary: Price respects a higher-low ascending trendline. Buyers defend $760, but $800+ remains heavy resistance. Breakdown below $760 risks a drop to ~$717. Breakout above $800 opens upside toward $950–970. Growth Catalysts: 1. Zepbound & Mounjaro dominate the obesity/diabetes sector. 2. Retatrutide & Orforglipron (next-gen obesity treatments) could further expand market share by 2026. 3. Revenue growth: ~45% YoY in Q4 2024. 4. Analysts forecast ~15% annual revenue growth and 20%+ EPS CAGR through 2027. Risks: 1. Q1 2025 saw adjusted EPS guidance trimmed to ~$20.78–22.28 from previous ~$22.50–24, causing ~7% drop in stock . 2. Valuation rich: forward P/E ~35 vs peers like Novo at ~14 3. 025 EPS estimates have slightly fallen (from $22.20 to $21.94) while 2026 expectations rose. 4. New rival Hengrui/Kailera shows ~18–19% weight loss, close to Zepbound’s ~21%, though still pre-approval 5. Regulatory volatility: Trump has floated heavy pharma tariffs (up to 200%) and repatriation incentives; Lilly has U.S. capacity but details remain uncertain Analyst Sentiment: Consensus target: $1,000+ within 12–24 months. MarketBeat & StockAnalysis rate LLY as Strong Buy. Institutional ownership remains high. What to Monitor Next 1. FDA approvals for orforglipron or retatrutide (expected late 2025). 2. Next earnings—watch for forward guidance recovery. 3. Policy shifts (potential tariffs on pharma imports). 4. Obesity drug competition (Novo Nordisk, Chinese biosimilars). Final Position: Modest Long Bias Eli Lilly is technically holding trendline support while fundamentally leading in a booming therapeutic sector. Together, this makes LLY a long-term buy, though caution near $760 is warranted. I tried to summaries as short as possible as i didn't want to make this post into an essay Please note this is not financial advice Sources Used for Analysis: 1. Eli Lilly Company Filings & Reports 2. Latest Earnings Reports (Q1 2025, prior Q4 2024) 3. Pipeline Updates and FDA Submission News 4. MarketBeat (Analyst ratings & price targets) 5. Yahoo Finance (EPS estimates, revenue growth forecasts) 6. StockAnalysis.com (Valuation ratios, dividend data) 7. Bloomberg and CNBC (News on guidance revisions) 8. Federal Reserve statements and forecasts 9. Bureau of Labor Statistics (BLS) – healthcare inflation data 10. WSJ and Financial Times – reporting on pharma tariffs and global healthcare policy shifts 11. Industry and Sector Insights 12. Novo Nordisk Investor Updates – competitor tracking 13. Statista – Obesity/diabetes global prevalence reports 14. World Health Organization (WHO) reports 15. Standard RSI and trendline patterns (based on TradingView style) 16. Support/resistance zones derived from historical price action Market Sentiment Tools 17. CNN Fear & Greed Index 18. S&P 500 Health Care Sector ETF (XLV) trends
NYSE:LLYLong
by Kristjan_Maximus
1
$LLY Technical Setup – Breakout ReloadingNYSE:LLY is holding a critical mid-range level, and the chart hints at a potential accumulation before a breakout. Here's the updated view: 🔹 Horizontal Range Still Intact: Price remains trapped between ~$710 support and ~$965 resistance. These levels have acted as major turning points for over a year — creating a defined trading range. 🔹 False Breakdown & Quick Recovery: After dipping below support, price quickly reclaimed the $795 level — often a signal of seller exhaustion and demand stepping in. This creates a potential bear trap scenario. 🔹 Rejection Zones Marked: Prior attempts to break above ~$965 have failed at the same zone (highlighted in blue), forming a strong but vulnerable ceiling. Each attempt weakens the resistance. 🔹 Current Structure Suggests Stair-Step Higher: Holding $795 could attract more buyers. A higher low formation would build pressure for a push toward the top of the range. Break and hold above $965 opens the door to ATH continuation. 🔹 Trade View: Entry: ~$790–$800 zone Stop: Below $709 (red zone — invalidation level) Target: $965, possibly higher if breakout confirms 💡 Why Price Could Rise: Price just reclaimed a key level that previously acted as a major pivot. Strong pharma sector sentiment and NYSE:LLY 's leadership in the GLP-1 space remain intact. Technical structure supports continuation of the larger range cycle. 🚫 Not financial advice — just charting the probabilities. Watch for confirmation!
NYSE:LLYLong
by Kristjan_Maximus
ELI LILLY Is starting its next big rally.Eli Lilly (LLY) is about to test its 1W MA50 (blue trend-line) following a rebound just below the 1W MA100 (green trend-line). The latter, has been the ultimate market Support since May 2018 (last time it broke below it). The overall correction since the July 15 2024 High seems like a Bull Flag pattern, no different than all the others after 2018 which only served as healthy rebalancing of an overbought price action. Based on he 1W RSI in particular and the Bullish Divergence it displayed, the current Bull Flag resembles more the March - October 2019 pattern. Both that and the next one reached their 2.0 Fibonacci extensions. As a result, our long-term Target on LLY is just below the 2.0 Fib at $1300. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
2
Eli Lillly $LLYNYSE:LLY – Long Setup Ahead of June FOMC Eli Lilly remains fundamentally strong, with robust growth in revenue (+45% YoY), driven by weight-loss and diabetes drugs like Mounjaro and Zepbound. Despite this, the stock saw a recent pullback after a lowered FY25 profit outlook. Technical View: LLY is trading near a key support zone around $710. The setup offers a favorable 1:5 risk/reward ratio, with a stop at $700.86 and a target near $768. Bollinger Bands are tightening, indicating a potential breakout. This decline could be partially driven by market caution ahead of the upcoming FOMC meeting in June. If support holds, we may see a bounce toward the $760–770 area. Plan: Entry: ~$710 Target: ~$768 Stop: ~$700.86 Risk/Reward: 1:5 Watching price action closely near the lower Bollinger band.
NYSE:LLYLong
by ALVO13_official
LLY Daily: Navigating Key Levels - Two Strategic OpportunitiesOVERVIEW: LLY has recently undergone a significant correction from its highs, finding strong demand at a crucial support zone. Price action now presents two distinct, high-probability long entry scenarios based on the stock's interaction with key horizontal levels. My analysis outlines potential entry points, clear targets, and risk management. KEY OBSERVATIONS & MARKET STRUCTURE: Major Demand Zone Established: Following a notable pullback in early May, LLY found substantial buying interest within the lower green horizontal zone (approximately $680 - $710). This area has acted as a robust "Support Trade" zone, preventing further downside and initiating a corrective bounce. Corrective Rally & Intermediate Resistance: From this strong support, LLY mounted a decent rally, completing a clear W-formation or basing pattern (highlighted by the orange and blue zig-zag lines). Price is currently interacting with an intermediate resistance level / supply zone (the upper grey/light green horizontal zone around $755 - $775). This level represents a critical point of contention between buyers and sellers. Two Strategic Entry Scenarios: The current market context offers two distinct long entry approaches, each with its own risk/reward profile: Scenario 1: Breakout Trade (Orange Ellipse / "1st Entry Above 775") A. Condition: This strategy focuses on a decisive breakout and sustained close above the current intermediate resistance level (approx. $775). A strong daily candle closing above this zone would confirm bullish momentum. B. Entry: Look for price action to confirm the breakout, potentially on a retest of the broken resistance now acting as support (as indicated by the orange arrow and ellipse). An entry above $775 is targeted here. C. Risk Management: A stop-loss should be placed just below the breakout level and the recent swing low, ideally around $745.33 (bottom of the red box). Scenario 2: Support Trade (Blue Ellipse / "2nd Entry 710") A. Condition: This strategy anticipates a potential rejection from the current intermediate resistance, leading to a pullback to the primary demand zone (approx. $710). B. Entry: Look for strong bullish reversal signals (e.g., bullish engulfing candle, hammer, demand zone rejection) if price retraces to the lower demand zone around $710 (indicated by the blue arrow and ellipse). This offers a potentially lower risk entry with a better risk-to-reward ratio for the same targets. C. Risk Management: A stop-loss would be positioned just below the main support zone, around $675.70 (bottom of the larger red box). POTENTIAL TARGETS: Regardless of the entry scenario, our upside targets remain consistent based on prior price structure and supply zones: • 1st Target: $860 (Green Zone): This is a significant resistance level from earlier price action, representing the first major hurdle for buyers. • 2nd Target: $920 (Upper Green Zone): This represents the ultimate upside target, aligning with the previous all-time highs and a major supply zone. INVALIDATION: • For "Breakout Trade" (1st Entry): A sustained daily close below $745.33 would invalidate this specific trade idea. • For "Support Trade" (2nd Entry): A sustained daily close below $675.70 would invalidate the entire bullish bias derived from the primary demand zone and suggest further downside is likely. CONCLUSION: LLY is presenting clear technical setups after finding substantial support. Traders can opt for an aggressive Breakout Trade if momentum sustains through intermediate resistance, or a more conservative Support Trade if price retraces to the established demand zone. Both strategies aim for significant upside potential towards $860 and $920, with clearly defined risk management levels. Risk Management is Paramount : Always adhere to your stop-loss and position sizing to protect your capital. This is not financial advice; do your own research. Disclaimer: The information provided in this chart is for educational and informational purposes only and should not be considered as investment advice. Trading and investing involve substantial risk and are not suitable for every investor. You should carefully consider your financial situation and consult with a financial advisor before making any investment decisions. The creator of this chart does not guarantee any specific outcome or profit and is not responsible for any losses incurred as a result of using this information. Past performance is not indicative of future results. Use this information at your own risk. This chart has been created for my own improvement in Trading and Investment Analysis. Please do your own analysis before any investments.
NYSE:LLYLong
by ManiMarkets
Eli Lilly Stock Down 10.9% Over Past YearTop or Consolidation? Here's My Take... It's not crystal clear — I can see the case for both. But after years of chart-watching, this doesn't quite look like a top to me: • Lacks symmetry • Had chances to break down, but no real follow-through 🧭 Where are we headed? I think pressure remains, and we could dip toward the 50% retracement of the 2023 move — that’s around 646. 🔁 If we bounce from there, I’ll shift my bias to a recovery and resumption of the long-term uptrend. Disclaimer: The information posted on Trading View is for informative purposes and is not intended to constitute advice in any form, including but not limited to investment, accounting, tax, legal or regulatory advice. The information therefore has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. Opinions expressed are our current opinions as of the date appearing on Trading View only. All illustrations, forecasts or hypothetical data are for illustrative purposes only. The Society of Technical Analysts Ltd does not make representation that the information provided is appropriate for use in all jurisdictions or by all Investors or other potential Investors. Parties are therefore responsible for compliance with applicable local laws and regulations. The Society of Technical Analysts will not be held liable for any loss or damage resulting directly or indirectly from the use of any information on this site.
NYSE:LLY
by The_STA